Faron Pharmaceuticals Oy Faron to Present at H.C. Wainwright Conference
07 Septiembre 2021 - 1:00AM
RNS Non-Regulatory
TIDMFARN
Faron Pharmaceuticals Oy
07 September 2021
Faron Pharmaceuticals Ltd
("Faron")
Faron to Present at the Virtual H.C. Wainwright Global Investor
Conference
TURKU, FINLAND / BOSTON, MA, September 7, 2021 - Faron
Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical
stage biopharmaceutical company focused on building the future of
immunotherapy by harnessing the power of the immune system to
tackle cancer and inflammation, today announced that Dr. Juho
Jalkanen, Chief Development Officer of Faron, will present at the
virtual H.C. Wainwright Global Investor Conference.
Dr. Jalkanen's presentation will be available on-demand starting
Monday, September 13, 2021 at 7:00 am EDT / 12:00 pm BST / 2:00 pm
EEST. You can access the presentation in the "Investors" section on
Faron's website at https://www.faron.com/investors .
ENDS
About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a clinical stage
biopharmaceutical company developing novel treatments for medical
conditions with significant unmet needs caused by dysfunction of
our immune system. Faron currently has a pipeline based on the
receptors involved in regulation of immune response in oncology,
organ damage and bone marrow regeneration. Bexmarilimab, a novel
anti-Clever-1 humanized antibody, is its investigative precision
immunotherapy with the potential to provide permanent immune
stimulation for difficult-to-treat cancers through targeting
myeloid function. Currently in Phase I/II clinical development as a
potential therapy for patients with untreatable solid tumors,
bexmarilimab has potential as a single-agent therapy or in
combination with other standard treatments including immune
checkpoint molecules. Traumakine is an investigational intravenous
(IV) interferon beta-1a therapy for the treatment of acute
respiratory distress syndrome (ARDS) and other ischemic or
hyperinflammatory conditions. Traumakine is currently being
evaluated in global trials as a potential treatment for
hospitalized patients with COVID-19 and with the 59th Medical Wing
of the US Air Force and the US Department of Defense for the
prevention of multiple organ dysfunction syndrome (MODS) after
ischemia-reperfusion injury caused by a major trauma. Faron is
based in Turku, Finland with operations in the United States.
Further
information is available at www.faron.com .
For more information please contact:
Media Contact
Eric Van Zanten
Head of Communications
Faron Pharmaceuticals Ltd
eric.vanzanten@faron.com
investor.relations@faron.com
Phone: +1 (610) 529-6219
Investor Contact
Stern Investor Relations
Julie Seidel
julie.seidel@sternir.com
Phone: +1 (212) 362-1200
Peel Hunt LLP, Broker
Dr Christopher Golden, James Steel
Phone: + 44 (0)20 7418 8900
Cairn Financial Advisers LLP, Nomad
Sandy Jamieson, Jo Turner, Mark Rogers
Phone: +44 (0)20 7213 0880
Sisu Partners Oy, Certified Adviser on Nasdaq First North
Juha Karttunen
Phone: +358 (0)40 555 4727
Jukka Järvelä
Phone: +358 (0)50 55 38 990
Consilium Strategic Communications
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
faron@consilium-comms.com
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRADKABPPBKDFCK
(END) Dow Jones Newswires
September 07, 2021 02:00 ET (06:00 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024